Annalise Bond

Annalise Bond

Auto-generated profile, based on publicly available information

Annalise Bond

Molecular Cellular and Developmental Biology Department, University of California; Santa Barbara, Santa Barbara, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
NJNoah Ray Johnson
Noah Ray Johnson
PYPeng Yuan
Peng Yuan
ECErika Castillo
Erika Castillo
TLT. Peter Lopez
T. Peter Lopez
WYWeizhou Yue
Weizhou Yue
CCCarlo Condello
Carlo Condello
Microglia are central to pathogenesis in many neurological conditions. Drugs targeting colony-stimulating factor-1 receptor (CSF1R) to block microglial proliferation in preclinical disease models have shown mixed outcomes, thus the therapeutic potential of this approach remains unclear. Here, we show that CSF1R inhibitors given by multiple dosing paradigms in the Tg2541 tauopathy mouse model cause a sex-independent reduction in pathogenic tau and reversion of non-microglial gene expression patterns toward a normal wild type signature. Despite greater drug exposure in male mice, only female mice have functional rescue and extended survival. A dose-dependent upregulation of immediate early genes and neurotransmitter dysregulation are observed in the brains of male mice only, indicating that excitotoxicity may preclude functional benefits. Drug-resilient microglia in male mice exhibit morphological and gene expression patterns consistent with increased neuroinflammatory signaling, suggesting a mechanistic basis for sex-specific excitotoxicity. Complete microglial ablation is neither required nor desirable for neuroprotection and therapeutics targeting microglia must consider sex-dependent effects.

16 December 2025 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JSJessica C. Stark
Jessica C. Stark
MGMelissa A. Gray
Melissa A. Gray
IIItziar Ibarlucea-Benitez
Itziar Ibarlucea-Benitez
MLMarta Lustig
Marta Lustig
ABAnnalise Bond
Annalise Bond
CBCarolyn Bertozzi
Carolyn Bertozzi
Despite the curative potential of checkpoint blockade immunotherapy, many patients remain unresponsive to existing treatments. Glyco-immune checkpoints, which involve interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors, have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular system for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin ‘decoy receptor’ domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate cancer cell destruction by primary human immune cells in vitro and reduce tumour burden in a humanized, immunocompetent mouse model, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumours and immune cell subsets as well as glyco-immune checkpoints, thus representing a potential modality for cancer immunotherapy.

16 October 2025 in Journal of Cell Biology
Verified
Journal Article
Closed access
WMWyatt D. Miller
Wyatt D. Miller
AMAndrew Manion
Andrew Manion
Abhinava MishraAbhinava Mishra
Abhinava Mishra
CSConnor John Sheedy
Connor John Sheedy
ABAnnalise Bond
Annalise Bond
MMMeghan A. Morrissey
Meghan A. Morrissey
CD47 on viable cells protects against phagocytosis. CD47 is recognized by SIRPα, an inhibitory receptor expressed by macrophages and other myeloid cells. Activated SIRPα recruits SHP-1 and SHP-2 phosphatases, but the inhibitory signaling cascade downstream of these phosphatases is unclear. Here, we used time-lapse imaging to measure how CD47 impacts the kinetics of phagocytosis. Targets with IgG antibodies were primarily phagocytosed through a Rac-based reaching mechanism. Targets also containing CD47 were only phagocytosed through a less frequent Rho-based sinking mechanism. Hyperactivating Rac2 eliminated the suppressive effect of CD47, suggesting that CD47 prevents activation of Rac and reaching phagocytosis. During IgG-mediated phagocytosis, the tyrosine kinase Syk phosphorylates the GEF Vav, which activates Rac to drive F-actin rearrangement and target internalization. CD47 inhibited Vav phosphorylation without impacting Vav recruitment to the phagocytic synapse or Syk phosphorylation. Macrophages expressing a hyperactive Vav were no longer sensitive to CD47. These data suggest that Vav is a key target of the CD47 signaling pathway.

12 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
WMWyatt D Miller
Wyatt D Miller
Abhinava MishraAbhinava Mishra
Abhinava Mishra
CSConnor John Sheedy
Connor John Sheedy
ABAnnalise Bond
Annalise Bond
BGBrooke Meghan Gardner
Brooke Meghan Gardner
MMMeghan A Morrissey
Meghan A Morrissey
Summary: CD47 is expressed by viable cells to protect against phagocytosis. CD47 is recognized by SIRPα, an inhibitory receptor expressed by macrophages and other myeloid cells. Activated SIRPα recruits SHP-1 and SHP-2 phosphatases but the inhibitory signaling cascade downstream of these phosphatases is not clear. In this study, we used time lapse imaging to measure how CD47 impacts the kinetics of phagocytosis. We found that targets with IgG antibodies were primarily phagocytosed through a Rac-based reaching mechanism. Targets also containing CD47 were only phagocytosed through a less frequent Rho-based sinking mechanism. Hyperactivating Rac2 eliminated the suppressive effect of CD47, suggesting that CD47 prevents activation of Rac and reaching phagocytosis. During IgG-mediated phagocytosis, the tyrosine kinase Syk phosphorylates the GEF Vav, which then activates the GTPase Rac to drive F-actin rearrangement and target internalization. CD47 inhibited Vav1 phosphorylation without impacting Vav1 recruitment to the phagocytic synapse or Syk phosphorylation. Macrophages expressing a hyperactive Vav1 were no longer sensitive to CD47. Together this data suggests that Vav1 is a key target of the CD47 signaling pathway.

14 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAnnalise Bond
Annalise Bond
SFSareen Fiaz
Sareen Fiaz
KRKirstin R Rollins
Kirstin R Rollins
JNJazz Elaiza Q Nario
Jazz Elaiza Q Nario
SRSamuel J Rosen
Samuel J Rosen
MMMeghan A Morrissey
Meghan A Morrissey
Summary: Macrophages measure the ‘eat-me’ signal IgG to identify targets for phagocytosis. We wondered if prior encounters with IgG influence macrophage appetite. IgG is recognized by the Fc Receptor. To temporally control Fc Receptor activation, we engineered an Fc Receptor that is activated by light-induced oligomerization of Cry2, triggering phagocytosis. Using this tool, we demonstrate that Fc Receptor activation primes macrophages to be more sensitive to IgG in future encounters. Macrophages that have previously experienced Fc Receptor activation eat more IgG-bound cancer cells. Increased phagocytosis occurs by two discrete mechanisms – a short- and long-term priming. Long term priming requires new protein synthesis and Erk activity. Short term priming does not require new protein synthesis and correlates with an increase in Fc Receptor mobility. Our work demonstrates that IgG primes macrophages for increased phagocytosis, suggesting that therapeutic antibodies may become more effective after initial priming doses.

27 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAnnalise Bond
Annalise Bond
ESErika T Snyder
Erika T Snyder
AMAndrew Manion
Andrew Manion
CHCatherine Hardy
Catherine Hardy
KKKenny Kieu
Kenny Kieu
MMMeghan A Morrissey
Meghan A Morrissey
Antibodies engage both activating Fc Receptors and the inhibitory receptor FcγRIIB. Why macrophages need a dedicated inhibitory receptor rather than simply tuning activating receptor signaling is unclear. Using DNA-based chimeric receptors and in silico modeling, we independently controlled activating and inhibitory Fc Receptors. We found that FcγRIIB imposed a time limit on macrophage phagocytosis and ERK signaling. The time limit is due to activating Fc Receptors converting PI(4,5)P2 to PI(3,4,5)P3, which is subsequently converted to PI(3,4)P2 by FcγRIIB. This leads to a pulse of active signaling, which is sufficient for phagocytosis of small bacteria-sized targets but not phagocytosis of large targets and TNFα secretion. Unlike engaging FcγRIIB, reducing activating Fc Receptor signaling decreased initiation of phagocytosis, the speed of PI(3,4,5)P3 generation, and the amplitude of ERK signaling. Our results demonstrate that FcγRIIB controls the duration of IgG signaling, while the activating Fc Receptors control sensitivity.